DiaSorin SpA engages in developing, producing and marketing reagent kits for laboratory diagnostics. The company is headquartered in Saluggia, Vercelli and currently employs 3,280 full-time employees. The company went IPO on 2007-07-19. The firm specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The firm develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. The company operates through ELISA immunodiagnostic business portfolio.
Mr. Carlo Rosa est le Chief Executive Officer de DiaSorin S.p.A., il a rejoint l'entreprise depuis 1998.
Quelle est la performance du prix de l'action DIASORIN SPA ?
Le prix actuel de DIASORIN SPA est de $70.76, il a diminué de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de DiaSorin S.p.A. ?
DiaSorin S.p.A. appartient à l'industrie Health Care et le secteur est Health Care
Quel est la capitalisation boursière de DiaSorin S.p.A. ?
La capitalisation boursière actuelle de DiaSorin S.p.A. est de $3.7B
Est-ce que DiaSorin S.p.A. est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 17 analystes ont établi des notations d'analystes pour DiaSorin S.p.A., y compris 3 achat fort, 8 achat, 5 maintien, 2 vente et 3 vente forte